Engineered enzyme erases a stubborn mark of aging by up to 70% in human tissue samples

A biotech company called Revel Pharmaceuticals is looking into ways to reverse aging, and the company's science team, along with researchers from the company Calico and the University of Colorado, may be a step closer to realizing the. The science-journalism coverage adds useful context, while the strongest evidential footing still comes from the underlying data, papers or institutional documentation.

This matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility: Add as preferred source Nature Communications (2026).

The team recently published their study in Nature Communications detailing how they engineered an enzyme capable of reversing a particular form of age-related damage and. Previous approaches to dealing with CML mostly focused on preventing new damage, leaving aged individuals with high accumulations of CML without recourse.

They screened more than 500 million enzyme variants for the ability to process CML. In laboratory-made damaged proteins, the CMLase enzyme reduced detectable CML by 52% and removed 97% when left to act overnight.

In proteins from a 64-year-old human eye, CMLase reduced total CML by 45% in one test, while CML was reduced by more than 70% in sections of elderly human arteries and by 55% in. Narisa Trabosh et al, Reversal of protein chemical aging by enzymatic deglycation, Nature Communications (2026).

The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.

Freelance science writer with Master's in physics. Editing for Science X since 2021.

Because this item comes through Phys. org Biology as science journalism, it should be treated as contextual reporting rather than primary evidence. Good science reporting can identify why a result matters, connect it to the wider literature and make technical work readable, but the decisive evidence remains in the original paper, dataset, mission release or technical record. That distinction is especially important when a story is later repeated by aggregators, because repetition increases visibility, not evidential strength.

The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.

Source